FIGURE 5.

Filgotinib AUC_0‐24 by the five most frequent grade 3/4 laboratory abnormalities in subjects with rheumatoid arthritis (RA). The analysis set includes subjects with RA who were enrolled/randomized, received at least one dose of filgotinib in studies FINCH 1, FINCH 2, FINCH 3, DARWIN 1, DARWIN 2 and DARWIN 3, and had at least one nonmissing pharmacokinetic (PK) parameter of interest. For each box, the bottom and top edges are located at the sample 25^th (Q1) and 75^th (Q3) percentiles, respectively, the centre horizontal line is drawn at the 50^th percentile (median) and outliners (beyond 1.5 × the interquartile range) are displayed as small squares. AUC_0‐24 is the population PK‐predicted exposure in phase 2 and phase 3 subjects with RA receiving filgotinib